• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 4. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

Recent Advances in the Application of 4,4,5,5-Tetramethyl-2-{5-methyl-1,1'-biphenyl-3-yl}-1,3,2-dioxaborolane (CAS: 1923743-78-5) in Chemical Biology and Pharmaceutical Research

The compound 4,4,5,5-tetramethyl-2-{5-methyl-1,1'-biphenyl-3-yl}-1,3,2-dioxaborolane (CAS: 1923743-78-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This boronic ester derivative is a key intermediate in Suzuki-Miyaura cross-coupling reactions, which are pivotal in the synthesis of complex organic molecules, including pharmaceuticals and agrochemicals. Recent studies have highlighted its utility in the development of novel therapeutic agents, particularly in oncology and infectious disease research.

One of the most notable applications of this compound is its role in the synthesis of kinase inhibitors. Kinases are critical targets in cancer therapy, and the ability to efficiently synthesize kinase inhibitors with high selectivity and potency is a major focus of current research. The boronic ester moiety in 4,4,5,5-tetramethyl-2-{5-methyl-1,1'-biphenyl-3-yl}-1,3,2-dioxaborolane facilitates the introduction of biphenyl groups into kinase inhibitor scaffolds, enhancing their binding affinity and pharmacokinetic properties. Recent studies have demonstrated its use in the synthesis of Bruton's tyrosine kinase (BTK) inhibitors, which are promising candidates for the treatment of B-cell malignancies.

In addition to its applications in oncology, this compound has also been explored in the context of infectious disease research. For instance, it has been employed in the synthesis of boron-containing antimicrobial agents. Boron-based compounds are increasingly recognized for their unique mechanisms of action, including the inhibition of bacterial enzymes such as β-lactamases. The incorporation of 4,4,5,5-tetramethyl-2-{5-methyl-1,1'-biphenyl-3-yl}-1,3,2-dioxaborolane into antimicrobial scaffolds has been shown to improve their stability and efficacy against drug-resistant pathogens.

Recent advancements in synthetic methodologies have further expanded the utility of this compound. For example, researchers have developed novel catalytic systems that enable the efficient cross-coupling of 4,4,5,5-tetramethyl-2-{5-methyl-1,1'-biphenyl-3-yl}-1,3,2-dioxaborolane with a wide range of electrophiles, including heteroaryl halides and triflates. These methodologies have significantly broadened the scope of accessible biphenyl derivatives, enabling the rapid exploration of structure-activity relationships in drug discovery programs.

Despite its promising applications, challenges remain in the large-scale synthesis and purification of 4,4,5,5-tetramethyl-2-{5-methyl-1,1'-biphenyl-3-yl}-1,3,2-dioxaborolane. Recent efforts have focused on optimizing reaction conditions to improve yield and reduce the formation of byproducts. Additionally, studies have investigated the stability of this compound under various storage conditions, providing valuable insights for its handling and use in industrial settings.

In conclusion, 4,4,5,5-tetramethyl-2-{5-methyl-1,1'-biphenyl-3-yl}-1,3,2-dioxaborolane (CAS: 1923743-78-5) represents a versatile and valuable tool in chemical biology and pharmaceutical research. Its applications in the synthesis of kinase inhibitors and antimicrobial agents underscore its potential to contribute to the development of next-generation therapeutics. Ongoing research efforts aimed at optimizing its synthesis and expanding its utility are expected to further enhance its impact in the field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)